skip to Main Content

SBRT Plus Pembrolizumab/Trametinib Demonstrate Potential for Treatment of Recurrent Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
The use of stereotactic body radiotherapy (SBRT) plus pembrolizumab (Keytruda) and trametinib (Mekinist) could be a potential novel treatment for patients with recurrent pancreatic cancer after surgery, according to the results of a phase 2 (NCT02704156) study published in Lancet Oncology.

Patients who received SBRT plus pembrolizumab and trametinib achieved a median overall survival (OS) of 24.9 months (95% CI, 23.3-26.5) compared with SBRT plus gemcitabine (Gemzar), which yielded a median OS of 22.4 months (95% CI, 0.44-0.82; HR, 0.60; 95% CI, 0.44-0.83; P = .0012). Investigators emphasize that a phase 3 trial is still needed in order to confirm the findings. The 2-year OS rate in the SBRT plus gemcitabine was 37.6% (95% CI, 32.3%-42.9%) and 56.5% (95% CI, 51.1%-61.9%) for the SBRT plus pembrolizumab and trametinib group. Read more . . . 


Back To Top